RxDoctor Payments Data

Micael Lopez-Acevedo

Gynecologic Oncology · Manati, PRNPI 1396903415

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $129,543 of the $160,762 with a category attached, or 80.6%. 10 manufacturers reported payments, led by AstraZeneca at 53.8% of the total. Reporting peaked in 2019 at $49,808 and has fallen 95.9% since, to $2,034 in 2025.

$160,762in general payments, 2019–2025

Across 149 payments — averaging $1078.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$87K
  • GSK$23K
  • AbbVie$22K
  • Eisai Inc.$18K
  • Merck$6K
  • Immunogen, Inc.$4K
  • plus $294 from 4 others

What the payments were for

  • Consulting fees$17,34611%
  • Speaking & faculty fees$129,54381%
  • Travel & lodging$9,6866%
  • Food & beverage$4,1883%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few gynecologic oncology providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Megestrol Acetate26$1,583
Medroxyprogesterone Acetate20$774
Tramadol Hcl63$256

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in Manati

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →